Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Pipeline
  • AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist
  • Pipeline

AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist

BioSpace

The lineup at the Alzheimer's Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurode

Neuroscience

Read full story

pharminent July 10, 2026 (Last updated: July 10, 2026)

BioSpace

The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurode

Neuroscience

Read full story

Post navigation

Previous: GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
Next: Hengrui-Kailera Oral GLP-1 Phase 3 Data Lands From China

Related Stories

  • Pipeline

Beyond GLP1s: The race for nextgen obesity drugs starts in the preclinical models

pharminent September 2, 2026
  • Pipeline

Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail

pharminent August 25, 2026
  • Pipeline

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

pharminent August 11, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.